RA Capital Management L.P. Sells 1,335,154 Shares of 10x Genomics $TXG

Key Points

• RA Capital Management L.P. decreased its stake in 10x Genomics by 40.7% in the first quarter, resulting in ownership of 1.59% of the company's shares valued at approximately $16.97 million.
• Several institutional investors, including GAMMA Investing LLC and PNC Financial Services Group Inc., increased their holdings in 10x Genomics during the same period.
• Brokerages have set varying target prices for 10x Genomics, with Morgan Stanley lowering theirs from $18.00 to $17.00, while UBS Group raised it from $12.00 to $13.00, indicating a mixed outlook from analysts.

RA Capital Management L.P. reduced its holdings in shares of 10x Genomics (NASDAQ:TXG - Free Report) by 40.7% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,944,247 shares of the company's stock after selling 1,335,154 shares during the quarter. RA Capital Management L.P. owned approximately 1.59% of 10x Genomics worth $16,973,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. GAMMA Investing LLC grew its stake in shares of 10x Genomics by 81.8% during the 1st quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock worth $31,000 after acquiring an additional 1,614 shares in the last quarter. Deutsche Bank AG grew its stake in shares of 10x Genomics by 35.3% during the 4th quarter. Deutsche Bank AG now owns 10,190 shares of the company's stock worth $146,000 after acquiring an additional 2,657 shares in the last quarter. Cetera Investment Advisers grew its stake in shares of 10x Genomics by 22.7% during the 4th quarter. Cetera Investment Advisers now owns 19,898 shares of the company's stock worth $286,000 after acquiring an additional 3,679 shares in the last quarter. Rhumbline Advisers grew its stake in shares of 10x Genomics by 11.4% during the 1st quarter. Rhumbline Advisers now owns 120,490 shares of the company's stock worth $1,052,000 after acquiring an additional 12,374 shares in the last quarter. Finally, Gotham Asset Management LLC bought a new position in shares of 10x Genomics during the 4th quarter worth approximately $264,000. 84.68% of the stock is owned by institutional investors.

Insider Activity at 10x Genomics

In other 10x Genomics news, CFO Adam Taich sold 22,315 shares of 10x Genomics stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $307,723.85. Following the transaction, the chief financial officer owned 309,273 shares in the company, valued at $4,264,874.67. The trade was a 6.73% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Benjamin J. Hindson sold 7,486 shares of 10x Genomics stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $103,231.94. Following the completion of the transaction, the insider owned 440,888 shares in the company, valued at approximately $6,079,845.52. This represents a 1.67% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 39,149 shares of company stock valued at $539,865 over the last quarter. 9.39% of the stock is owned by corporate insiders.

10x Genomics Price Performance

TXG stock traded up $0.23 during midday trading on Thursday, reaching $13.57. 1,709,156 shares of the company were exchanged, compared to its average volume of 2,840,047. The business has a 50-day moving average price of $13.10 and a two-hundred day moving average price of $10.74. 10x Genomics has a one year low of $6.78 and a one year high of $24.38. The firm has a market capitalization of $1.69 billion, a price-to-earnings ratio of -19.39 and a beta of 2.00.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported $0.28 earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.63. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The company had revenue of $172.91 million during the quarter, compared to the consensus estimate of $139.36 million. During the same quarter last year, the firm earned ($0.32) earnings per share. The company's revenue was up 12.9% on a year-over-year basis. 10x Genomics has set its Q3 2025 guidance at EPS. As a group, analysts anticipate that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on TXG shares. Wall Street Zen raised shares of 10x Genomics from a "hold" rating to a "buy" rating in a research note on Saturday, August 9th. Morgan Stanley decreased their target price on shares of 10x Genomics from $18.00 to $17.00 and set an "overweight" rating for the company in a research note on Tuesday, August 12th. Weiss Ratings reissued a "sell (e+)" rating on shares of 10x Genomics in a research note on Saturday, August 30th. Bank of America raised their target price on shares of 10x Genomics from $12.00 to $13.00 and gave the company a "neutral" rating in a research note on Thursday, June 26th. Finally, The Goldman Sachs Group decreased their target price on shares of 10x Genomics from $7.50 to $6.50 and set a "sell" rating for the company in a research note on Monday, May 12th. Six research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $13.54.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.